References
- Chilewski SD , MoraJR, GleasonC, DeSilvaB. Addressing matrix effects in ligand-binding assays through the use of new reagents and technology. Bioanalysis6 (8), 1059–1067 (2014).
- de Dios K , ManibusanA, MarsdenR, PinkstaffJ. Comparison of bioanalytical methods for the quantitation of PEGylated human insulin. J. Immunol. Methods396 (1–2), 1–7 (2013).
- Dudal S , BaltrukonisD, CrisinoRet al. Assay formats: recommendation for best practices and harmonization from the global bioanalysis consortium harmonization team. AAPS J. 16 (2), 194–205 (2014).
- Fraley KJ , AbberleyL, HottensteinCS, UlicneJJ, CiteroneDR, SzapacsME. The Gyrolab immunoassay system: a platform for automated bioanalysis and rapid sample turnaround. Bioanalysis5 (14), 1765–1774 (2013).
- Fraser S , DysingerM, SoderstromC, KuhnM, DurhamR. Active glucagon-like peptide 1 quantitation in human plasma: a comparison of multiple ligand binding assay platforms. J. Immunol. Methods407, 76–81 (2014).
- Given AM , WhalenPM, O’BrienPJ, RayCA. Development and validation of an alpha fetoprotein immunoassay using Gyros technology. J. Pharm. Biomed. Anal. 64–65, 8–15 (2012).
- Jonsson O , SteffenAC, SundquistVSet al. Capillary microsampling and analysis of 4-microl blood, plasma and serum samples to determine human alpha-synuclein elimination rate in mice. Bioanalysis5 (4), 449–462 (2013).
- Joyce AP , WangM, Lawrence-HendersonRet al. One mouse, one pharmacokinetic profile: quantitative whole blood serial sampling for biotherapeutics. Pharm. Res. 31 (7), 1823–1833 (2014).
- Liu R , PillutlaR, DeSilvaB, ZhangYJ. Rapid development of multiple ‘fit-for-purpose’ assays on an automatic microfluidic system using a streamlined process in support of early biotherapeutics discovery programs. Bioanalysis5 (14), 1751–1763 (2013).
- Liu XF , WangX, WeaverRJet al. Validation of a Gyrolab assay for quantification of rituximab in human serum. J. Pharmacol. Toxicol. Methods65 (3), 107–114 (2012).
- Lund T , MangsboSM, ScholzHet al. Resolvin E1 reduces proinflammatory markers in human pancreatic islets in vitro. Exp. Clin. Endocrinol. Diabetes118 (4), 237–244 (2010).
- Mora JR , Obenauer-KutnerL, VimalPV. Application of the Gyrolab platform to ligand-binding assays: a user’s perspective. Bioanalysis2 (10), 1711–1715 (2010).
- Myler HA , GivenA, KolzK, MoraJR, HristopoulosG. Biotherapeutic bioanalysis: a multi-indication case study review. Bioanalysis3 (6), 623–643 (2011).
- Rivera E , EkholmPF, InganasM, PaulieS, GronvikKO. The Rb1 fraction of ginseng elicits a balanced Th1 and Th2 immune response. Vaccine23 (46–47), 5411–5419 (2005).
- Roman J , QiuJ, DornadulaG, HamuroL, BakhtiarR, VerchT. Application of miniaturized immunoassays to discovery pharmacokinetic bioanalysis. J. Pharmacol. Toxicol. Methods63 (3), 227–235 (2011).
- Salimi-Moosavi H , RathanaswamiP, RajendranS, ToupikovM, HillJ. Rapid affinity measurement of protein-protein interactions in a microfluidic platform. Anal. Biochem. 426 (2), 134–141 (2012).
- Jordan G , Moheysen-ZadehM, HeinrichJ, StaackRF. Platform switching from ELISA to Gyrolab: a novel generic reagent omits the need to change critical reagents. Bioanalysis8 (8), 807–814 (2016).
- Myzithras M , LiH, BigwarfeTet al. Development of an ultra-sensitive Simoa assay to enable GDF11 detection: a comparison across bioanalytical platforms. Bioanalysis8 (6), 511–518 (2016).
- Collet-Brose J , CoublePJ, DeehanMR, NelsonRJ, FerlinWG, LoryS. Evaluation of multiple immunoassay technology platforms to select the anti-drug antibody assay exhibiting the most appropriate drug and target tolerance. J. Immunol. Res. 2016, 5069678 (2016).
- Stubenrauch K , WesselsU, EssigU, VogelR, SchleypenJ. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies. J. Pharm. Biomed. Anal. 52 (2), 249–254 (2010).